Wan Nazaimoon, W.M. and Ismail, I.S. and Tan, H.J. and Kamaruddin, N.A. and Khalid, A.K. (2004) Vascular Cell Adhesion Molecule-l (VCAM-l) in Graves' Disease: Its Association to Thyroid Status and Thyroid Receptor Stimulating Antibodies. International Journal of Endocrinology and Metabolism, 2 (2). pp. 66-73.
![[img]](http://eprints.um.edu.my/style/images/fileicons/application_pdf.png)
|
PDF
Vascular_cell_adhesion_molecule.pdf - Published Version Download (423kB) |
Abstract
Soluble vascular cell adhesion molecule-1 (sVCAM-1) and intercellular adhesion molecule-1 (sICAM-1) have been shown to be elevated in patients with Graves� disease and may play significant roles in the pathogenesis of the disease. The objective of this study was to measure the levels of sVCAM-1, sICAM-1, IL-6 and thyroid receptor stimulating antibodies (TRAb) in a cohort of hyperthyroid patients and determine their associations to thyroid hormones status, before and after 3 months therapy with carbimazole. Materials and Methods: Patients were given fixed daily dose of 20 mg carbimazole for 3 months and blood samples were collected at baseline and end of the study. Thirty eight patients were recruited from the Endocrine Clinic, Hospital University Kebangsaan Malaysia, con-sisting of 26 females and 12 males, age ranging from 16 to 65 years. Blood samples collected be-fore and at end of study were analyzed for TSH, Free T3, Free T4, thyroid receptor stimulating anti-bodies (TRAb), sVCAM-1, sICAM-1 and IL-6. Results: TRAb level of ?10 U/L was taken to be negative, while TRAb level of >10 U/L was considered as positive. Twenty-six patients (68) were TRAb positive (TRAb+) and 12 patients (30) were TRAb negative (TRAb-). Median TRAb in TRAb+ patients was 23 U/L at baseline, declining to 16.7 U/L (p<0.001) in the third 3 month. Serum sVCAM-1 levels were signifi-cantly elevated in TRAb+ patients compared to TRAb- (860 versus 499 ng/mL, p<0.001). The level decreased significantly to 537 ng/mL with treat-ment but remained higher than in TRAb- patients (p=0.003). Irrespective of TRAb status, all but one patient had elevated serum sICAM-1 levels that remained unaffected by carbimazole therapy. In contrast, IL-6 levels of hyperthyroid patients were within the reference range of 1.4-14.1 pg/mL. Baseline and post-treatment sVCAM-1, and not TRAb levels, were significantly corre-lated to thyroid hormones. Conclusion: Compared to other inflammatory markers, sVCAM-1 showed significant correlation to thyroid stimulating antibodies and was most sensitive to changes in thyroid status. The significance of these findings in relation to Graves� disease warrants further investigation.
| Item Type: | Article |
|---|---|
| Funders: | UNSPECIFIED |
| Uncontrolled Keywords: | VCAM-1; GRAVES; DISEASE; TRAB; INFLAMMATION |
| Subjects: | R Medicine |
| Divisions: | Faculty of Medicine |
| Depositing User: | Ms Haslinda Lahuddin |
| Date Deposited: | 12 Jul 2013 01:27 |
| Last Modified: | 12 Dec 2014 01:23 |
| URI: | http://eprints.um.edu.my/id/eprint/7227 |
Actions (login required)
 |
View Item |
